Advantages to the Marrow Cellution™ System

  • Reduce the Cost of Utilizing Biologics

    The Marrow Cellution™ System delivers a regenerative solution at a reduced cost compared to the industry leading solutions.

  • Minimize O/R Time

    Centrifugation systems typically require 20 minutes or more of spin time during the surgical procedure, not to mention the additional personnel (i.e. perfusion) and support time needed for preparation and cleanup of the equipment.

  • Minimize Sterility Challenges

    Centrifugation systems require passing the BMA off the sterile field for processing and back on for implantation. The Marrow Cellution™ System eliminates the additional steps where infection concerns must be managed.

  • Minimize Sample Waste

    Centrifugation systems typically discard 80% of the aspirate due to the high levels of peripheral blood. Worse, significant numbers of the desired cells (approx. 40%) are discarded because as these cells increase in density prior to division, they are processed into the undesired red cell centrifuge component and thus discarded, substantially limiting the regenerative potential of the resulting sample.

  • Minimize Use of Anti-Coagulants

    Centrifugation systems require at least 10% dilution by volume for the addition of anti-coagulant to allow the sample to separate, and also require another 10% dilution in the form of a neutralizing agent such as thrombin and calcium chloride in order for the marrow to clot in the graft. The Marrow Cellution™ System eliminates these requirements.

  • Eliminate the Need to Filter

    Protocols require the marrow to be filtered prior to centrifugation. Cells bound within a cell aggregate can be delivered to the patient when mixed with graft material or injected. This is not the case when aggregates are filtered out prior to centrifugation. Filtering takes additional time, but more importantly, filtering reduces regenerative potential.

Benefits at a Glance

Less peripheral blood in the sample

Single acquisition site

20 minute procedure

Low discomfort for the patient

Average 3000 CFU’s per ml

Very low host morbidity

*Qualifies under newly released FDA Guidance criteria*